EPS for InflaRx N.V. (IFRX) Expected At $-0.44; Avid Technology Has 1.63 Sentiment

Avid Technology, Inc. (NASDAQ:AVID) Logo

Avid Technology Inc (AVID) investors sentiment increased to 1.63 in 2018 Q4. It’s up 0.74, from 0.89 in 2018Q3. The ratio is positive, as 44 investment managers increased and started new holdings, while 27 sold and reduced positions in Avid Technology Inc. The investment managers in our database now possess: 23.21 million shares, up from 22.04 million shares in 2018Q3. Also, the number of investment managers holding Avid Technology Inc in top ten holdings was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 20 Increased: 24 New Position: 20.

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.44 EPS on April, 4.After having $-0.31 EPS previously, InflaRx N.V.’s analysts see 41.94% EPS growth. The stock decreased 2.51% or $1.22 during the last trading session, reaching $47.4. About 283,960 shares traded or 142.81% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 17, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “ING Italy to strengthen compliance – Nasdaq” on March 16, 2019, also Nasdaq.com with their article: “Hydrogenics Reports Fourth Quarter and Full Year 2018 Results – Nasdaq” published on March 15, 2019, Nasdaq.com published: “Village Farms’ Cannabis Operation Achieves Profitability; Stock Pops 7% – Nasdaq” on March 14, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Methanex’s (MEOH) Board Approves 5% Share Buyback Program – Nasdaq” with publication date: March 13, 2019.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $1.22 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Avid Technology, Inc. develops, markets, sells, and supports software and hardware for digital media content production, management, and distribution worldwide. The company has market cap of $260.74 million. The firm offers professional video creative tools, such as Media Composer product line that is used to edit video content; NewsCutter option and iNews systems for news production; Avid Symphony option, which is used during post-production; and Media Composer | Cloud solution that enables broadcast news professionals to acquire, access, edit, and finish stories. It currently has negative earnings. It also offers media management solutions comprising Avid MediaCentral | UX Web and mobile apps that provide real-time access to media assets for media professional; and Avid Interplay asset management solutions, which offers network, storage, and database solutions to enable users to simultaneously share and manage media assets across a project or organization.

Cove Street Capital Llc holds 3.98% of its portfolio in Avid Technology, Inc. for 6.48 million shares. Private Capital Management Llc owns 1.18 million shares or 0.93% of their US portfolio. Moreover, Eam Investors Llc has 0.38% invested in the company for 295,738 shares. The California-based Rbf Capital Llc has invested 0.19% in the stock. New England Private Wealth Advisors Llc, a Massachusetts-based fund reported 101,226 shares.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *